61 Results

People

  1. Kelsen
    Kelsen
  2. Casper
    Casper
  3. Aghajanian
    Aghajanian
  4. Schwartz
    Schwartz
  5. Bajorin
    Bajorin
  6. De Angelis
    De Angelis
  7. Lassman
    Lassman
  8. Motzer
    Motzer
  9. O'Reilly
    O'Reilly
  10. Abou-Alfa
    Abou-Alfa

Groups

  1. Department of Medicine (45)
  2. Solid Tumor Oncology Division (34)
  3. Hematologic Malignancies, Division of (13)
  4. Center for Pancreatic Cancer Research (11)
  5. Gastrointestinal Oncology Service (9)
  6. Biostatistics Service (8)
  7. Center for Hematologic Malignancies (8)
  8. Epidemiology and Biostatistics (8)
  9. Genitourinary Oncology Service (8)
  10. Surgery (8)
  1. "phase ii"
Formats
  1. Journal Article (49)
  2. Meeting Abstract (12)
Groups
  1. Department of Medicine (45)
  2. Solid Tumor Oncology Division (34)
  3. Hematologic Malignancies, Division of (13)
  4. Center for Pancreatic Cancer Research (11)
  5. Gastrointestinal Oncology Service (9)
  6. Biostatistics Service (8)

More Groups

People
  1. David Kelsen (7)
  2. Ephraim Casper (6)
  3. Carol Aghajanian (5)
  4. Gary Schwartz (5)
  5. Dean Bajorin (4)
  6. Andrew Lassman (3)

More People

Years
  1. 2024 (2)
  2. 2023 (8)
  3. 2022 (4)
  4. 2019 (2)
  5. 2018 (1)
  6. 2017 (1)

More Years

Publications
  1. Investigational New Drugs (14)
  2. Clinical Lymphoma, Myeloma and Leukemia (11)
  3. Gynecologic Oncology (6)
  4. International Journal of Radiation Oncology, Biology, Physics (5)
  5. Cancer (3)
  6. European Journal of Cancer (3)

More Publications

Publishers
  1. Elsevier Inc. (28)
  2. Springer (16)
  3. Oxford University Press (3)
  4. Wiley Blackwell (3)
  5. Elsevier Science, Inc. (2)
  6. Lippincott Williams & Wilkins (2)

More Publishers

Results (61)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
    Journal Article

    Fury, M. G.; Zahalsky, A.; Wong, R.; Venkatraman, E.; Lis, E.; Hann, L.; Aliff, T.; Gerald, W.; Fleisher, M.; Pfister, D. G.
    Investigational New Drugs (2007)

    Fulltext@MSK | Save
  • A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
    Journal Article

    Duran, I.; Kortmansky, J.; Singh, D.; Hirte, H.; Kocha, W.; Goss, G.; Le, L.; Oza, A.; Nicklee, T.; Ho, J.; more...
    British Journal of Cancer (2006)

    Fulltext@MSK | Save
  • A multicenter phase II study of bortezomib in recurrent or metastatic sarcomas
    Journal Article

    Maki, R. G.; Kraft, A. S.; Scheu, K.; Yamada, J.; Wadler, S.; Antonescu, C. R.; Wright, J. J.; Schwartz, G. K.
    Cancer (2005)

    Fulltext@MSK | Save
  • A phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers
    Journal Article

    Abou-Alfa, G. K.; Rowinsky, E. K.; Patt, Y. Z.; Schwartz, G. K.; Kelsen, D. P.; Sharma, S.; Siegel, E.; Becerra, C. R.; Eckhardt, S. G.; Feit, K.; more...
    American Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors
    Journal Article

    Kondagunta, G. V.; Bacik, J.; Schwartz, L.; Sheinfeld, J.; Bajorin, D.; Vuky, J.; Marion, S.; Mazumdar, M.; Bosl, G. J.; Motzer, R. J.
    Investigational New Drugs (2004)

    Fulltext@MSK | Save
  • Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: Associations with clinical characteristics, pathophysiological variables and toxicity
    Journal Article

    Puchalski, T. A.; Ryan, D. P.; Garcia-Carbonero, R.; Demetri, G. D.; Butkiewicz, L.; Harmon, D.; Seiden, M. V.; Maki, R. G.; Lopez-Lazaro, L.; Jimeno, J.; more...
    Cancer Chemotherapy and Pharmacology (2002)

    Fulltext@MSK | Save
  • An optimal two-stage phase II design utilizing complete and partial response information separately
    Journal Article

    Panageas, K. S.; Smith, A.; Gonen, M.; Chapman, P. B.
    Controlled Clinical Trials (2002)

    Fulltext@MSK | Save
  • The phase II/III transition: Toward the proof of efficacy in cancer clinical trials
    Journal Article

    Fazzari, M.; Heller, G.; Scher, H. I.
    Controlled Clinical Trials (2000)

    Fulltext@MSK | Save
  • A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma
    Journal Article

    O'Reilly, E. M.; Ilson, D. H.; Saltz, L. B.; Heelan, R.; Martin, L.; Kelsen, D. P.
    Cancer Investigation (1999)

    Fulltext@MSK | Save
  • Phase II trial of topotecan in advanced breast cancer: A Cancer and Leukemia Group B study
    Journal Article

    Levine, E. G.; Cirrincione, C. T.; Szatrowski, T. P.; Canellos, G.; Norton, L.; Craig Henderson, I.
    American Journal of Clinical Oncology (1999)

    Fulltext@MSK | Save